Reports

Ideas That Generate Results

List of Figures:

Figure 3-1: ADC - Mechanism of Action
Figure 4-1: Global - ADC Market (Billion US$), 2014-2020
Figure 4-2: Global - ADCETRIS Market (Million US$), 2011-2013
Figure 4-3: Global - ADCETRIS Market (Billion US$), 2014-2020
Figure 4-4: Global - Kadcyla Market (Billion US$), 2014-2020
Figure 5-1: Pipeline ADCs by Clinical Phase (2014)
Figure 5-2: Pipeline ADCs by Indication (2014)
Figure 5-3: Pipeline ADCs by Drug (2014)

List of Tables:

Table 4-1: Potential Patients for ADCETRIS (2012)
Table 4-2: Ongoing Trials for ADCETRIS
Table 4-3: Potential Patients for Kadcyla (2012)
Table 4-4: Ongoing Trials for Kadcyla
Table 7-1: ADCs in Pipeline
Table 9-1: Strategic Collaborations in ADC Industry
Table 10-1: Top Companies by ADCs in Pipeline (2014)
Table 10-2: Seattle Genetics - ADCs in Pipeline
Table 10-3: Seattle Genetics - ADCs Collaborator Pipeline
Table 10-4: Seattle Genetics - Strengths and Weaknesses
Table 10-5: Roche - ADC Collaborator Pipeline
Table 10-6: Roche - Strengths and Weaknesses
Table 10-7: Immunogen, Inc. - ADCs in Pipeline
Table 10-8: Immunogen, Inc. - ADC Collaborator Pipeline
Table 10-9: Immunogen, Inc. - Strengths and Weaknesses
Table 10-10: Bayer Healthcare - ADCs in Pipeline
Table 10-11: Bayer Healthcare - Strengths and Weaknesses
Table 10-12: Novartis Pharmaceuticals - ADCs in Pipeline
Table 10-13: Novartis Pharmaceuticals - Strengths and Weaknesses
Table 10-14: Immunomedics - ADCs in Pipeline
Table 10-15: Immunomedics - Strengths and Weaknesses
Table 10-16: Agensys, Inc. - ADC Collaborator Pipeline
Table 10-17: Agensys, Inc. - Strengths and Weaknesses